Advertisement

Topics

PubMed Journals Articles About "Lodotra Rheumatoid Arthritis" RSS

19:58 EDT 16th October 2018 | BioPortfolio

Lodotra Rheumatoid Arthritis PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Lodotra Rheumatoid Arthritis articles that have been published worldwide.

More Information about "Lodotra Rheumatoid Arthritis" on BioPortfolio

We have published hundreds of Lodotra Rheumatoid Arthritis news stories on BioPortfolio along with dozens of Lodotra Rheumatoid Arthritis Clinical Trials and PubMed Articles about Lodotra Rheumatoid Arthritis for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lodotra Rheumatoid Arthritis Companies in our database. You can also find out about relevant Lodotra Rheumatoid Arthritis Drugs and Medications on this site too.

Showing "Lodotra Rheumatoid Arthritis" PubMed Articles 1–25 of 1,100+

MICB*002 and MICB*014 protect against rheumatoid arthritis, whereas MICA*009 and MICA*A6 are associated with rheumatoid arthritis in a Hainan Han Chinese population.

Rheumatoid arthritis (RA) as an inflammatory autoimmune disease affects the synovial joints as well as other organs and tissues. Since aberrant expression of MIC molecules has been observed in RA patient, MIC genotypes might play certain roles in the development of RA.


Methotrexate did not improve endothelial function in rheumatoid arthritis: a study in rats with adjuvant-induced arthritis.

Rheumatoid arthritis is associated with an increased cardiovascular risk, secondary to endothelial dysfunction. There is accumulating evidence that methotrexate reduces cardiovascular risk in rheumatoid arthritis, but the mechanisms involved are still unknown. In this study, we aimed to determine the effect of methotrexate on endothelial function and traditional cardiovascular risk factors in the adjuvant-induced arthritis (AIA) rat model.

Effects of TNF-α in rheumatoid arthritis via attenuating α1 (I) collagen promoter.

To explore the role of TNF-α in the peripheral blood of patients with rheumatoid arthritis (RA) and its underlying mechanism.


Rheumatoid arthritis in remission : Decreased myostatin and increased serum levels of periostin.

Chronic inflammation of rheumatoid arthritis (RA) is associated with disturbances in muscle and bone metabolism.

Recombinant interferon alpha 2b in rheumatoid arthritis: good antigen for rheumatoid arthritis antibodies.

Interferon alpha-induced arthritis and activation of the type 1 interferon pathway during rheumatoid arthritis (RA) has been well documented but the underlying mechanism remains unclear. This study addressed the binding specificity of antibodies with recombinant interferon alpha 2b (rIFN -2b) in sera from different RA patients. Utilization of anti-hrIFN -2b antibodies as a probe for estimation of interferon -2b concentration in RA patients' synovial fluid (SF) was also investigated.

Comprehensive evaluation of finger flexor tendon entheseal soft tissue and bone changes by ultrasound can differentiate psoriatic arthritis and rheumatoid arthritis.

To determine whether a detailed sonographic evaluation of the hand flexor tendon compartment could help differentiate between psoriatic arthritis (PsA) and rheumatoid arthritis (RA).

​ Cultural adaptation of the Rheumatoid Arthritis Quality of Life (RAQoL) for Portugal.

Rheumatoid Arthritis (RA) is a chronic inflammatory disease that has a major impact on patients´ quality of life. The Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire is a patient-reported outcome measure, specific to RA. The aim of this study was to translate and perform the cross-cultural adaptation of the RAQoL into Portuguese.

Plasma lipidomic profile signature of rheumatoid arthritis versus Lyme arthritis patients.

Distinguishing of rheumatoid arthritis (RA) and Lyme arthritis (LA) is difficult, because of similar symptoms. This presents a significant clinical problem since treatments are quite different in both diseases. We investigated the plasma phospholipid profiles of RA and LA patients versus healthy subjects to find metabolic changes responsible for differentiation of both diseases.

Treatment effect of CDKN1A on rheumatoid arthritis by mediating proliferation and invasion of fibroblast-like synoviocytes cells.

The objective of the present study was to evaluate the role of CDKN1A in rheumatoid arthritis (RA).

The association of obesity with disease activity, functional ability and quality of life in early rheumatoid arthritis: data from the Early Rheumatoid Arthritis Study/Early Rheumatoid Arthritis Network UK prospective cohorts.

To examine associations between BMI and disease activity, functional ability and quality of life in RA.

Cost of biologic treatment persistence or switching in rheumatoid arthritis.

To estimate total costs among patients with rheumatoid arthritis (RA) who persisted on or switched from newly initiated biologic therapy.

Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis.

Recent advances in knowledge of the pathogenesis of rheumatoid arthritis (RA) has led to promoting very early intervention.

Accurately Determining Proper Shoe Size in Patients With Rheumatoid Arthritis.

The aim of this descriptive study was to determine whether people with rheumatoid arthritis (RA) wear adequately fitting footwear.

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Biologic disease-modifying antirheumatic drugs (bDMARDs) have revolutionised treatment and outcomes for rheumatoid arthritis (RA). The expanding repertoire allows the option of switching bDMARD if current treatment is not effective. For some patients, even after switching, disease control remains elusive. This analysis aims to quantify the frequency of, and identify factors associated with, bDMARD refractory disease.

Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis.

Neoangiogenesis is a crucial event to promote the development of the hyperplasic proliferative pathologic synovium in Rheumatoid arthritis (RA). Ultrasound (US) is sensitive for detection of power Doppler (PD) vascularization.

Body fat percentage, waist circumference and obesity as risk factors for rheumatoid arthritis - A Danish cohort study.

To investigate the relationship between bioimpedance-derived total body fat percentage, waist circumference (WC) and Body Mass Index (BMI) and the subsequent development of rheumatoid arthritis (RA).

Exercise for rheumatoid arthritis of the hand.

Rheumatoid arthritis is an inflammatory polyarthritis that frequently affects the hands and wrists. Hand exercises are prescribed to improve mobility and strength, and thereby hand function.

Identification of Key Genes and Pathways in Rheumatoid Arthritis Gene Expression Profile by Bioinformatics.

The aim of this study was to identify potential key candidate genes and uncover their potential mechanisms in rheumatoid arthritis.

Identification of Key Genes and Pathways in Rheumatoid Arthritis Gene Expression Profile by Bioinformatics.

The aim of this study was to identify potential key candidate genes and uncover their potential mechanisms in rheumatoid arthritis.

Dihydromyricetin relieves rheumatoid arthritis symptoms and suppresses expression of pro-inflammatory cytokines via the activation of Nrf2 pathway in rheumatoid arthritis model.

Rheumatoid arthritis (RA) is a systemic inflammatory and autoimmune disease. In this research, we estimated the protective effects of Dihydromyricetin (DMY) on RA induced by Complete Freund's Adjuvant (CFA). We found that DMY effectively relieved rheumatoid arthritis symptoms, such as body weight change, paw swelling and rheumatoid arthritis scores. In addition, we also observed that DMY significantly lowered the immune organ indexes (including thymus and spleen) and exhibited the anti-inflammatory effect i...

Talk to your gut: the oral-gut microbiome axis and its immunomodulatory role in the etiology of rheumatoid arthritis.

Microbial communities inhabiting the human body, collectively called the microbiome, are critical modulators of immunity. This notion is underpinned by associations between changes in the microbiome and particular autoimmune disorders. Specifically, in rheumatoid arthritis, one of the most frequently occurring autoimmune disorders worldwide, changes in the oral and gut microbiomes have been implicated in the loss of tolerance against self-antigens and in increased inflammatory events promoting the damage of...

Rheumatoid Arthritis: A Brief Overview of the Treatment.

Rheumatoid arthritis (RA) is a chronic inflammatory systemic autoimmune disease, affecting the joints with varying severity among patients. The risk factors include age, gender, genetics and environmental exposure (cigarette smoking, air pollutants and occupational). Many complications can follow such as permanent joint damage requiring arthroplasty, rheumatoid vasculitis and elty's syndrome requiring splenectomy if it remains unaddressed. As there is no cure for RA, the treatment goals are to reduce the pa...

Usefulness of tocilizumab for treating rheumatoid arthritis with myelodysplastic syndrome: A case report and literature review.

Dysregulated immune function in rheumatoid arthritis (RA) might lead to the development of myelodysplastic syndrome (MDS). Serum interleukin-6 (IL-6) concentrations are increased in both RA and MDS patients.

Two-year adherence and costs for biologic therapy for rheumatoid arthritis.

To evaluate adherence to newly initiated biologic disease-modifying antirheumatic drugs (bDMARDs) in effectively treated patients with rheumatoid arthritis (RA).

Treatment delays for patients with new onset rheumatoid arthritis presenting to an Australian early arthritis clinic.

Early treatment ensures optimal outcomes in rheumatoid arthritis (RA). This study aimed to quantify treatment delays in RA patients and to explore factors influencing delay and resultant patient outcomes.


Advertisement
Quick Search
Advertisement
Advertisement